Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Seeing Is Believing: GSK Pledges To Upgrade Key Antibiotics Plant As Witty Hosts Q3 Call From Singapore

This article was originally published in PharmAsia News

Executive Summary

During a celebration to mark GSK’s 40th year in Singapore, CEO Andrew Witty announces new investments in work-horse manufacturing plants and reaffirms openness to share patient data from clinical studies.

You may also be interested in...



Abandoned AstraZeneca Compounds “Given” To U.K. R&D Academics

AstraZeneca is giving 15 shelved compounds to U.K.-based academics in a collaboration funded by public money that may produce scientific breakthroughs along with thorny IP issues.

Glaxo Opens Its Clinical Trial Library To Encourage Drug Development

GlaxoSmithKline, previously punished for holding back key medical information, is making its huge library of clinical trial data available to scientists in an effort promote drug discovery and show that it hides no secrets.

GSK’s Oncology Expansion Heavily Dependent On Dabrafenib, Trametinib

GlaxoSmithKline announced NDA filings for BRAF inhibitor dabrafenib and MEK inhibitor trametinib in metastatic melanoma on Aug. 3. The two compounds represent one-quarter of the company’s novel oncology agents in clinical development, according to the most recent pipeline update.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC079776

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel